Roberta Rampton
Roberta Rampton is NPR's White House editor. She joined the Washington Desk in October 2019 after spending more than six years as a White House correspondent for Reuters. Rampton traveled around America and to more than 20 countries covering President Trump, President Obama and their vice presidents, reporting on a broad range of political, economic and foreign policy topics. Earlier in her career, Rampton covered energy and agriculture policy.
-
President Trump took questions from reporters for the first time since he lost the election to Joe Biden. He said he'll leave the White House on Jan. 20, but made clear he won't concede.
-
The president has made it clear that he will spend his remaining days in the White House in the same way he spent much of his term in office: fighting.
-
President Trump slumped in polls and fundraising — and lost 10 days when he caught the coronavirus. He threw everything into reaching for a come-from-behind win, but Democrat Joe Biden beat him.
-
President Trump is racing across swing states in the homestretch of the election, making his closing arguments as he finds himself down in the polls.
-
Olivia Troye said President Trump prioritized his reelection over concern for people getting sick. Trump said Thursday she was a "lower-level person" who was terminated.
-
The vice president says President Trump "sees America for what it is" and has the track record to help the country recover from the pandemic and grapple with protests against racism.
-
The first lady, not often one for the spotlight, addressed the Republican National Convention on Tuesday from the White House Rose Garden. Watch her full remarks.
-
Kodak has struggled in the age of digital photography. Its stock soared after the Trump administration announced plans to give the company a $765 million loan to create a pharmaceutical line.
-
The president on Monday rejects calls to disband or defund police departments. But he said, "We're going to talk about ideas how we can do it better."
-
The impact of the drug on the virus is being studied, but there is not yet evidence from medical trials — and there have been some warnings about side effects from taking the medicine.